ATE553201T1 - Hepatitis c virus genotypsequenzen sowie ihre verwendung als behandlungs- und nachweismittel - Google Patents

Hepatitis c virus genotypsequenzen sowie ihre verwendung als behandlungs- und nachweismittel

Info

Publication number
ATE553201T1
ATE553201T1 AT99118783T AT99118783T ATE553201T1 AT E553201 T1 ATE553201 T1 AT E553201T1 AT 99118783 T AT99118783 T AT 99118783T AT 99118783 T AT99118783 T AT 99118783T AT E553201 T1 ATE553201 T1 AT E553201T1
Authority
AT
Austria
Prior art keywords
hepatitis
treatment
sequences
present
virus genotype
Prior art date
Application number
AT99118783T
Other languages
English (en)
Inventor
Geert Maertens
Lieven Stuyver
Original Assignee
Innogenetics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogenetics Nv filed Critical Innogenetics Nv
Application granted granted Critical
Publication of ATE553201T1 publication Critical patent/ATE553201T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT99118783T 1993-04-27 1994-04-27 Hepatitis c virus genotypsequenzen sowie ihre verwendung als behandlungs- und nachweismittel ATE553201T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP93401099 1993-04-27
EP93402019 1993-08-05

Publications (1)

Publication Number Publication Date
ATE553201T1 true ATE553201T1 (de) 2012-04-15

Family

ID=26134679

Family Applications (4)

Application Number Title Priority Date Filing Date
AT94915550T ATE373093T1 (de) 1993-04-27 1994-04-27 Sequenzen der genotype des hepatitis-c-virus sowie ihre verwendung als arzneimitteln und diagnostika
AT99118785T ATE552340T1 (de) 1993-04-27 1994-04-27 Hepatitis c virus genotypsequenzen sowie ihre verwendung als behandlungs- und nachweismitteln
AT99118783T ATE553201T1 (de) 1993-04-27 1994-04-27 Hepatitis c virus genotypsequenzen sowie ihre verwendung als behandlungs- und nachweismittel
AT99118784T ATE551423T1 (de) 1993-04-27 1994-04-27 Sequenzen von hepatitis c virus-genotypen sowie ihre verwendungen als therapeutika und diagnostika

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AT94915550T ATE373093T1 (de) 1993-04-27 1994-04-27 Sequenzen der genotype des hepatitis-c-virus sowie ihre verwendung als arzneimitteln und diagnostika
AT99118785T ATE552340T1 (de) 1993-04-27 1994-04-27 Hepatitis c virus genotypsequenzen sowie ihre verwendung als behandlungs- und nachweismitteln

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT99118784T ATE551423T1 (de) 1993-04-27 1994-04-27 Sequenzen von hepatitis c virus-genotypen sowie ihre verwendungen als therapeutika und diagnostika

Country Status (15)

Country Link
US (3) US6762024B2 (de)
EP (4) EP1004670B1 (de)
JP (5) JPH07508423A (de)
CN (1) CN1108030A (de)
AT (4) ATE373093T1 (de)
AU (1) AU688323B2 (de)
BR (1) BR9405334A (de)
CA (2) CA2139100C (de)
DE (1) DE69435023T2 (de)
ES (1) ES2294779T3 (de)
FI (1) FI946066A0 (de)
NO (1) NO944967L (de)
NZ (1) NZ266148A (de)
SG (1) SG50563A1 (de)
WO (1) WO1994025601A2 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010239A2 (en) 1991-11-21 1993-05-27 Common Services Agency Hepatitis-c virus testing
US6709828B1 (en) 1992-03-06 2004-03-23 N.V. Innogenetics S.A. Process for the determination of peptides corresponding to immunologically important epitopes and their use in a process for determination of antibodies or biotinylated peptides corresponding to immunologically important epitopes, a process for preparing them and compositions containing them
US6667387B1 (en) 1996-09-30 2003-12-23 N.V. Innogenetics S.A. HCV core peptides
US6380376B1 (en) * 1992-10-30 2002-04-30 Iowa State University Research Foundation Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV)
US7258977B1 (en) * 1992-11-27 2007-08-21 Innogenetics N.V. Process for typing of HCV isolates
CA2139100C (en) 1993-04-27 2009-06-23 Geert Maertens New sequences of hepatitis c virus genotypes and their use as therapeutic and diagnostic agents
US7255997B1 (en) 1993-04-27 2007-08-14 N.V. Innogenetics S.A. Sequences of hepatitis C virus genotypes and their use as therapeutic and diagnostic agents
ES2231773T3 (es) 1993-05-05 2005-05-16 Common Services Agency Virus de la hepatitis c de tipo 4, 5 y 6.
US7070790B1 (en) 1993-06-29 2006-07-04 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 and core genes of isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
US5514539A (en) * 1993-06-29 1996-05-07 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
US5882852A (en) * 1993-06-29 1999-03-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Hepatitic C virus (HCV) core gene nucleotide sequences and related methods of detecting major and minor genotypes of HCV isolates
EP0804584B2 (de) * 1994-10-21 2008-07-09 Innogenetics N.V. Sequenzen von hepatitis-c-virus genotype 7, und deren verwendung als vorbeugende, therapeutische und diagnostische mittel
US5851759A (en) * 1996-04-19 1998-12-22 Chiron Corporation Heteroduplex tracking assay (HTA) for genotyping HCV
EP2298900A1 (de) 1996-09-17 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Zusammensetzungen und Verfahren zur Behandlung intrazellulärer Erkrankungen
TR200003024T2 (tr) 1998-04-17 2000-12-21 Innogenetics N.V. İndirgeme ajanlarını kullanarak geliştirilen immünodiagnostik tahliller.
DE19980730D2 (de) * 1998-04-28 2001-05-10 Wolfgang Bergter Radioimmunpharmaka zur Therapie der Hepatitis C
WO1999063941A2 (en) * 1998-06-09 1999-12-16 Branch Andrea D Novel hepatitis c virus peptides and uses thereof
US7052830B1 (en) 1998-06-09 2006-05-30 Branch Andrea D Hepatitis C virus peptides and uses thereof
ATE368221T1 (de) * 2000-06-15 2007-08-15 Novartis Vaccines & Diagnostic Immunoassays für anti-hcv-antikörper
US7022830B2 (en) * 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
US6858590B2 (en) * 2000-08-17 2005-02-22 Tripep Ab Vaccines containing ribavirin and methods of use thereof
AU9215101A (en) * 2000-08-17 2002-02-25 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US6680059B2 (en) * 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US7196183B2 (en) * 2001-08-31 2007-03-27 Innogenetics N.V. Hepatitis C virus genotype, and its use as prophylactic, therapeutic and diagnostic agent
MD2149G2 (ro) * 2001-11-23 2003-10-31 Институт Генетики И Физиологии Растений Академии Наук Молдовы Primer oligonucleotidic pentru depistarea ARN-ului virusului hepatitei C
PT1490383E (pt) * 2002-03-11 2009-05-25 Lab 21 Ltd Métodos e composições para identificar e caracterizar a hepatite c
AU2003254585A1 (en) 2002-07-24 2004-02-16 Intercell Ag Antigens encoded by alternative reading frame from pathogenic viruses
EP2402026A3 (de) 2002-09-13 2012-04-18 Intercell AG Verfahren zum Isolieren von Hepatitis-C-Virus-Peptiden
JP4676426B2 (ja) 2003-03-24 2011-04-27 インターツェル・アクチェンゲゼルシャフト 改良型ワクチン
JP4734241B2 (ja) 2003-07-11 2011-07-27 インターツェル・アクチェンゲゼルシャフト Ｈｃｖワクチン
ES2596753T3 (es) 2003-08-29 2017-01-11 Fujirebio Europe N.V. Nuevo clado del virus de la hepatitis C y secuencias prototipo del mismo
CN1977050B (zh) * 2004-01-07 2012-09-05 第三次浪潮技术公司 丙型肝炎病毒基因型的确定
US20060162667A1 (en) * 2005-01-26 2006-07-27 Papadoyianis Ernest D Aquatic habitat and ecological tank
US7968697B2 (en) * 2005-05-25 2011-06-28 Chrontech Pharma Ab Hepatitis C virus non-structural NS3/4A fusion gene
US7465561B2 (en) 2005-06-30 2008-12-16 Roche Molecular Systems, Inc. Probes and methods for hepatitis C virus typing using single probe analysis
MD3300G2 (ro) * 2006-09-28 2007-11-30 Институт Генетики, Физиологии И Защиты Растений Академии Наук Молдовы Primer oligonucleotidic pentru depistarea ARN-ului virusului hepatitei C
EP2121991A2 (de) 2006-10-20 2009-11-25 Innogenetics N.V. Methodik zur analyse von sequenzvariationen innerhalb des hcv-ns3/4a-genombereichs
US20090325145A1 (en) 2006-10-20 2009-12-31 Erwin Sablon Methodology for analysis of sequence variations within the hcv ns5b genomic region
WO2008046922A2 (en) * 2006-10-20 2008-04-24 Innogenetics N.V. Methodology for anaysis of sequence variations within the hcv ns5b genomic region
WO2009022939A1 (fr) * 2007-08-09 2009-02-19 Uchrezhdenie Rossiiskoi Akademii Nauk Institut Molekulyarnoi Biologii Im. V.A. Engelgardta Ran (Imb Ran) Procédé d'identification du génotype et du sous-type du virus de l'hépatite c sur une biopuce
WO2009022236A2 (en) 2007-08-16 2009-02-19 Tripep Ab Immunogen platform
US20090214593A1 (en) * 2007-08-16 2009-08-27 Tripep Ab Immunogen platform
CN101842498A (zh) * 2007-10-30 2010-09-22 英特芒尼公司 Hcv基因型分型和表型分型
CN102378914B (zh) * 2009-03-30 2014-12-10 生物梅里埃公司 用于hcv检测的固体支持物
WO2013150450A1 (en) * 2012-04-02 2013-10-10 Universidade Do Porto Hcv homolog fragments, cell-lines and applications thereof
US10267803B2 (en) * 2015-03-27 2019-04-23 Ortho-Clinical Diagnostics, Inc. HCV NS4A/modified NS3 polypeptides and uses thereof
CN109642253A (zh) * 2016-08-02 2019-04-16 豪夫迈·罗氏有限公司 用于提高核酸的扩增和检测/定量的效率的辅助寡核苷酸

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02500880A (ja) * 1987-11-18 1990-03-29 カイロン　コーポレイション Ｎａｎｂｖの診断用薬およびワクチン
US5350671A (en) 1987-11-18 1994-09-27 Chiron Corporation HCV immunoassays employing C domain antigens
GB2236819B (en) * 1989-09-14 1993-07-14 Gen Motors France Dual master cylinder
CA2065287C (en) * 1989-09-15 1999-12-21 Tatsuo Miyamura New hcv isolates
US5372928A (en) 1989-09-15 1994-12-13 Chiron Corporation Hepatitis C virus isolates
LU87861A1 (fr) 1989-12-18 1991-10-08 Wellcome Found Agent viral
EP0435229A1 (de) * 1989-12-27 1991-07-03 Sanwa Kagaku Kenkyusho Co., Ltd. DNS-Gen von einem Non-A Non-B Hepatitis-Virus, seine Klonierung und Verwendung
WO1991014779A1 (en) * 1990-03-28 1991-10-03 Mitsui Toatsu Chemicals, Incorporated Diagnostic for hepatitis virus
EP0461863A1 (de) * 1990-06-12 1991-12-18 Immuno Japan Inc. Oligonukleotid-Primer und ihre Anwendung zum Nachweis von non-A, non-B-Hepatitisvirus mit grosser Genauigkeit
NZ238681A (en) 1990-06-25 1992-03-26 Univ Osaka Res Found Non-a, non-b hepatitis virus particles and their production
DK0644202T3 (da) 1990-12-14 1997-09-15 Innogenetics Nv Syntetiske antigener til påvisning af antistoffer imod hepatitis C virus
EP0510952A1 (de) * 1991-04-26 1992-10-28 Immuno Japan Inc. Oligonukleotid-Primer und ihre Anwendung zum Nachweis von Non-A, Non-B-Hepatitis mit höchster Genauigkeit
ATE252154T1 (de) * 1991-05-08 2003-11-15 Chiron Corp Genomische hcv-sequenzen für diagnostik und therapie
ES2188583T3 (es) 1991-06-24 2003-07-01 Chiron Corp Polipeptidos para el virus de la hepatitis c (hcv).
EP0532167A3 (en) * 1991-08-09 1993-03-31 Immuno Japan Inc. Non-a, non-b hepatitis virus genome, polynucleotides, polypeptides, antigen, antibody and detection systems
CA2115926A1 (en) * 1991-08-21 1993-03-04 Stephen H. Dailey Hepatitis c assay utilizing recombinant antigens to ns1
ES2182822T3 (es) 1991-09-13 2003-03-16 Chiron Corp Composiciones de polipeptidos inmunorreactivos del virus de la hepatitis c.
WO1993010239A2 (en) * 1991-11-21 1993-05-27 Common Services Agency Hepatitis-c virus testing
ES2133529T3 (es) * 1992-11-27 1999-09-16 Innogenetics Nv Procedimiento para tipificar aislamientos de hcv.
CA2139100C (en) 1993-04-27 2009-06-23 Geert Maertens New sequences of hepatitis c virus genotypes and their use as therapeutic and diagnostic agents
UA46707C2 (uk) 1993-05-10 2002-06-17 Чірон Корпорейшн Спосіб типування вірусу гепатиту с (варіанти), набір поліпептидів (варіанти), реагент, що включає комбінацію поліпептидів, які містять типоспецифічні епітопи гепатиту с (варіанти)
JPH06319563A (ja) 1993-05-13 1994-11-22 Imuno Japan:Kk Ｃ型肝炎ウイルス遺伝子、オリゴヌクレオチド、並びにｃ型 肝炎ウイルス遺伝子型判定方法
US5882852A (en) 1993-06-29 1999-03-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Hepatitic C virus (HCV) core gene nucleotide sequences and related methods of detecting major and minor genotypes of HCV isolates
US5514539A (en) * 1993-06-29 1996-05-07 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
JP2687852B2 (ja) * 1993-10-13 1997-12-08 日本電気株式会社 半導体メモリ装置

Also Published As

Publication number Publication date
EP0651807A1 (de) 1995-05-10
US6762024B2 (en) 2004-07-13
WO1994025601A2 (en) 1994-11-10
NZ266148A (en) 1997-06-24
CA2139100C (en) 2009-06-23
EP0984068A2 (de) 2000-03-08
JP2004041206A (ja) 2004-02-12
ATE373093T1 (de) 2007-09-15
EP0984067A2 (de) 2000-03-08
CA2662090A1 (en) 1994-11-10
EP1004670B1 (de) 2012-04-11
EP0984067A3 (de) 2000-09-27
JP2002233388A (ja) 2002-08-20
US7195765B2 (en) 2007-03-27
EP0984068B1 (de) 2012-03-28
CN1108030A (zh) 1995-09-06
CA2139100A1 (en) 1994-11-10
JP2002233389A (ja) 2002-08-20
US20030008274A1 (en) 2003-01-09
FI946066A (fi) 1994-12-23
EP0651807B1 (de) 2007-09-12
ATE552340T1 (de) 2012-04-15
NO944967D0 (no) 1994-12-21
EP1004670A2 (de) 2000-05-31
AU688323B2 (en) 1998-03-12
NO944967L (no) 1994-12-21
BR9405334A (pt) 1999-05-25
SG50563A1 (en) 1998-07-20
ES2294779T3 (es) 2008-04-01
US7157226B1 (en) 2007-01-02
AU6722294A (en) 1994-11-21
JPH07508423A (ja) 1995-09-21
FI946066A0 (fi) 1994-12-23
EP0984067B1 (de) 2012-04-04
US20030032005A1 (en) 2003-02-13
WO1994025601A3 (en) 1995-03-02
DE69435023D1 (de) 2007-10-25
DE69435023T2 (de) 2008-09-11
ATE551423T1 (de) 2012-04-15
JP2004041207A (ja) 2004-02-12
EP0984068A3 (de) 2000-09-20
EP1004670A3 (de) 2000-09-20

Similar Documents

Publication Publication Date Title
ATE553201T1 (de) Hepatitis c virus genotypsequenzen sowie ihre verwendung als behandlungs- und nachweismittel
DK0637342T3 (da) Fremgangsmåde til typebestemmelse af HCV-isolater
DK0804584T3 (da) Sekvenser af hepatitis C virus genotype 7 og deres anvendelse som profylaktiske, terapeutiske og diagnostiske midler
WO1992019743A3 (en) Hcv genomic sequences for diagnostics and therapeutics
RU93058449A (ru) Hcv геномные последовательности для диагностических и терапевтических целей
DK0770679T4 (da) HCV-specifikke peptider, sammensætninger dertil og anvendelse deraf
ATE244729T1 (de) Verfahren zur identifizierung von wirkstoffen gegen hcv durch verwendung von strukturkoordinaten der hepatitis-c-virus- protease
NZ319786A (en) HCV NS3 protein fragments with helicase activity and improved solubility
DE69125066T2 (de) cDNS-Sequenz und Detektion des Hepatitis C-Virus
ATE115964T1 (de) Non-a non-b sequenzen.
TW369600B (en) Antigenic peptides for grouping hepatitis C virus, kit comprising the same and methods for its grouping the same